

Pharmacy and Therapeutics Committee Meeting
June 1, 2004
Kellogg Hotel and Conference Center

Draft Minutes

Committee Members Attending

Giovannino Perri, M.D., moderator
Robert Coffey, Pharm.D.
Robert Ernst, M.D.
Justus Feichtner, M.D.
Jonathan Henry, M.D.
Richard Slaughter, M.Sc.
Dean Van Loo, Pharm.D.

Other Attending

R. Michael Massanara, M.D.

Committee Members Absent, with Prior Notification

Debera Eggleston, M.D.
Max Robins, D.O.

Representatives of the Department of Community Health Attending

Susan Moran, Director, Bureau of Medicaid Program Operations and Quality Assurance
George Baker, M.D., Chief Medical Consultant, Children's Special Health Care Services
Jacqueline Coleman, Pharmacy Policy Analyst
Bradley Sprecher, Pharmacy Section Analyst

Representatives of First Health Services Corporation Attending

Annette Paul, R.Ph., Clinical Manager, Michigan Medicaid
Luenetta Jackson, Pharm.D., Michigan Account Manager

Public Audience

Approximately 70 persons attended.

Proceedings

I. Dr. Giovannino Perri opened the meeting at 6:05 p.m. Introductions were made, especially welcoming Richard Slaughter as the newly appointed chair, and J. Fiechtner and Dean Van Loo as new committee members.

II. Dr. Perri moderated during the Public Comment period. Speakers are listed in the order of presentation:

- Marcus Farbstein, Genentech: Raptiva
- Cher Beilfuss, Pharm.D., Amgen: Sensipar
- Aneel Mukir, Pharm.D., TAP: NapraPAC
- Rosemary Berardi, Pharm.D. Novartis: Zelnorm
- Arthur Hughett, M.D., Eli Lilly & Co.: Symbyax
- Dr. Barbara Micaulckis, M.D., Pfizer: Spiriva
- Khan Nedd, M.D., Grand Rapids African American Health Institute:
Combination Anti-Hypertensive Agents
- Sheila Koszycki, Pharm.D., GSK: Wellbutrin XL

III. Approval of Minutes

The minutes of the March meeting were inadvertently omitted from the packets. They will be sent to the committee by e-mail.

IV. New Drug Reviews

The Committee considered the new drugs for review and made the following recommendations:

- Sensipar: add to coverage without PA, review prescriber information at 3 and 6 months
- NapraPAC: continue PA for this product (Dr. Fiechtner abstained from voting.)
- Raptiva: add to coverage without PA
- Symbyax: this product shall be added to the PDL with prior authorization
- Levitra and Cialis: these products shall require PA according to the same criteria as Viagra
- Elestat: add to coverage without PA
- Alimta: add to coverage without PA

V. Review of PDL Categories

The Committee first reviewed work-group recommendations for the Cardiac drug classes and made the following recommendations to the Department:

The Committee recommended retaining the current class coverage structure for the following Cardiac drug classes:

<i>Angiotensin Receptor Antagonists</i>	<i>Coronary Vasodilators – Topical</i>
<i>Beta Blockers</i>	<i>Lipotropics – Fibrin Acid</i>
<i>Calcium Channel Blockers –</i>	<i>Derivatives</i>
<i>Dihydropyridine</i>	<i>Lipotropics – Non-Statins</i>
<i>Calcium Channel Blockers – Non-</i>	<i>Lipotropics – Niacin Derivatives</i>
<i>Dihydropyridine</i>	<i>Lipotropics – Other</i>
<i>Coronary Vasodilators – Oral</i>	<i>Platelet Inhibitors</i>

The Committee recommended retaining the current class coverage structure for the ACE inhibitors, with one abstention (Dr. Coffey).

The Committee recommended combining the *Lipotropics – Statins* and *Lipotropic – Statins for High Risk* categories. It also recommended removing the prior authorization requirement from Zocor ® and requiring prior authorization for Crestor ®. Dr. Feichtner dissented from the Crestor ® decision, but votes in the affirmative carried.

After the Cardiac classes, the Committee considered the work-group recommendations for the Central Nervous System (CNS) drug classes, and made the following recommendations to the Department:

The Committee recommended retaining the current class coverage structure for the following CNS drug classes:

<i>Alzheimer's Dementia</i>	<i>Antipsychotics – Typical</i>
<i>Anti-Anxiety – General</i>	<i>Drugs for ADD</i>
<i>Anti-Depressants – Tricyclics</i>	<i>Sedative Hypnotic Non-Barbiturates</i>
<i>Antipsychotics – Atypical</i>	

In the *Anti-Depressants – Other* class, the Committee recommended adding coverage for Effexor XR ®, without prior authorization. All other current class coverage structures within the class should remain.

In the *Anti-Depressants – SSRIS* class, the committee recommended requiring prior authorization for beneficiaries under the age of 18 for all drugs in the class, excepting Fluoxetine. All other current class coverage structures within the class should remain.

The Committee also recommended a prior authorization requirement for Symbyax ® under the *Bi-Polar Disorders* category.

Adjournment

The meeting adjourned at 9:30 (?) p.m.

Next Meeting is Tuesday, September 14th, 2004

6:00 P.M. – 9:00 P.M.

Kellogg Hotel and Conference Center

Respectfully submitted by Brad Sprecher